Myeloid cell factor-1 is a critical survival factor for multiple myeloma - PubMed (original) (raw)
. 2002 Mar 15;99(6):1885-93.
doi: 10.1182/blood.v99.6.1885.
Affiliations
- PMID: 11877256
- DOI: 10.1182/blood.v99.6.1885
Free article
Myeloid cell factor-1 is a critical survival factor for multiple myeloma
Bin Zhang et al. Blood. 2002.
Free article
Abstract
Multiple myeloma (MM) is characterized by the accumulation of malignant plasma cells in the bone marrow caused primarily by failure of normal homeostatic mechanisms to prevent the expansion of postgerminal center plasma cells. We have examined the molecular mechanisms that promote the survival of MM cells and have identified a key role for myeloid cell factor-1 (Mcl-1), an antiapoptotic member of the Bcl-2 family. These experiments were initiated by the observation that MM cells were exquisitely sensitive to culture in the presence of actinomycin D: caspase activation occurred within 3 hours of treatment and cells were not protected by interleukin-6, the main MM cell growth and survival factor. Actinomycin D-induced apoptosis was blocked by proteasome inhibitors, suggesting that a labile protein was required for MM cell survival. Further analysis demonstrated that Mcl-1 was likely to be the labile factor governing MM cell survival. Mcl-1 protein levels decreased rapidly after culture in the presence of actinomycin D in concordance with effector caspase activation, but addition of proteasome inhibitors reversed the loss of Mcl-1 and maintained cell viability. The levels of other antiapoptotic proteins, including Bcl-2 and members of the inhibitors-of-apoptosis family, were unaffected by these interventions. Furthermore, Mcl-1 antisense oligonucleotides caused a rapid down-regulation of Mcl-1 protein levels and the coincident induction of apoptosis, whereas overexpression of Mcl-1 delayed actinomycin D-induced apoptosis with kinetics that correlated with expression levels of Mcl-1. These data indicate that Mcl-1 expression is required for the survival of MM cells and may represent an important target for future therapeutics.
Similar articles
- Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma.
Gupta VA, Matulis SM, Conage-Pough JE, Nooka AK, Kaufman JL, Lonial S, Boise LH. Gupta VA, et al. Blood. 2017 Apr 6;129(14):1969-1979. doi: 10.1182/blood-2016-10-745059. Epub 2017 Feb 1. Blood. 2017. PMID: 28151428 Free PMC article. - Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.
Derenne S, Monia B, Dean NM, Taylor JK, Rapp MJ, Harousseau JL, Bataille R, Amiot M. Derenne S, et al. Blood. 2002 Jul 1;100(1):194-9. doi: 10.1182/blood.v100.1.194. Blood. 2002. PMID: 12070027 - Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma.
Gomez-Bougie P, Wuillème-Toumi S, Ménoret E, Trichet V, Robillard N, Philippe M, Bataille R, Amiot M. Gomez-Bougie P, et al. Cancer Res. 2007 Jun 1;67(11):5418-24. doi: 10.1158/0008-5472.CAN-06-4322. Cancer Res. 2007. PMID: 17545623 - Mcl-1 is a potential therapeutic target in multiple types of cancer.
Akgul C. Akgul C. Cell Mol Life Sci. 2009 Apr;66(8):1326-36. doi: 10.1007/s00018-008-8637-6. Cell Mol Life Sci. 2009. PMID: 19099185 Free PMC article. Review. - Mcl-1 Inhibition: Managing Malignancy in Multiple Myeloma.
Al-Odat O, von Suskil M, Chitren R, Elbezanti W, Srivastava S, Budak-Alpddogan T, Jonnalagadda S, Aggarwal B, Pandey M. Al-Odat O, et al. Front Pharmacol. 2021 Jul 19;12:699629. doi: 10.3389/fphar.2021.699629. eCollection 2021. Front Pharmacol. 2021. PMID: 34349655 Free PMC article. Review.
Cited by
- The phosphatase of regenerating liver-3 (PRL-3) is important for IL-6-mediated survival of myeloma cells.
Slørdahl TS, Abdollahi P, Vandsemb EN, Rampa C, Misund K, Baranowska KA, Westhrin M, Waage A, Rø TB, Børset M. Slørdahl TS, et al. Oncotarget. 2016 May 10;7(19):27295-306. doi: 10.18632/oncotarget.8422. Oncotarget. 2016. PMID: 27036022 Free PMC article. - TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
Sagawa M, Tabayashi T, Kimura Y, Tomikawa T, Nemoto-Anan T, Watanabe R, Tokuhira M, Ri M, Hashimoto Y, Iida S, Kizaki M. Sagawa M, et al. Cancer Sci. 2015 Apr;106(4):438-46. doi: 10.1111/cas.12616. Epub 2015 Mar 10. Cancer Sci. 2015. PMID: 25613668 Free PMC article. - A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells.
Jourdan M, Veyrune JL, De Vos J, Redal N, Couderc G, Klein B. Jourdan M, et al. Oncogene. 2003 May 15;22(19):2950-9. doi: 10.1038/sj.onc.1206423. Oncogene. 2003. PMID: 12771946 Free PMC article. - Conformational changes in Bcl-2 pro-survival proteins determine their capacity to bind ligands.
Lee EF, Czabotar PE, Yang H, Sleebs BE, Lessene G, Colman PM, Smith BJ, Fairlie WD. Lee EF, et al. J Biol Chem. 2009 Oct 30;284(44):30508-17. doi: 10.1074/jbc.M109.040725. Epub 2009 Sep 2. J Biol Chem. 2009. PMID: 19726685 Free PMC article. - Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90.
Zhao M, Ma J, Zhu HY, Zhang XH, Du ZY, Xu YJ, Yu XD. Zhao M, et al. Mol Cancer. 2011 Aug 29;10:104. doi: 10.1186/1476-4598-10-104. Mol Cancer. 2011. PMID: 21871133 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials